Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) EBT (2016 - 2026)

Perspective Therapeutics' EBT history spans 17 years, with the latest figure at -$26.2 million for Q1 2026.

  • On a quarterly basis, EBT fell 44.08% to -$26.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$8.0 million, a 90.72% increase, with the full-year FY2024 number at -$80.0 million, down 99.44% from a year prior.
  • EBT hit -$26.2 million in Q1 2026 for Perspective Therapeutics, down from $66.1 million in the prior quarter.
  • Over the last five years, EBT for CATX hit a ceiling of $66.1 million in Q4 2025 and a floor of -$41.8 million in Q4 2024.
  • Historically, EBT has averaged -$9.5 million across 5 years, with a median of -$11.1 million in 2023.
  • Biggest five-year swings in EBT: tumbled 707.05% in 2023 and later soared 258.14% in 2025.
  • Tracing CATX's EBT over 5 years: stood at -$7.3 million in 2022, then fell by 5.97% to -$7.8 million in 2023, then tumbled by 438.12% to -$41.8 million in 2024, then soared by 258.14% to $66.1 million in 2025, then plummeted by 139.59% to -$26.2 million in 2026.
  • Business Quant data shows EBT for CATX at -$26.2 million in Q1 2026, $66.1 million in Q4 2025, and -$26.0 million in Q3 2025.